(19)
(11) EP 4 798 186 A1

(12)

(43) Date of publication:
02.09.2026 Bulletin 2026/36

(21) Application number: 24883449.1

(22) Date of filing: 25.10.2024
(51) International Patent Classification (IPC): 
A61K 31/352(2006.01)
A61K 47/26(2006.01)
A23F 5/00(2025.01)
A61K 9/06(2006.01)
A23L 2/00(2006.01)
A23L 33/105(2016.01)
A23F 3/00(2025.01)
A61K 31/05(2006.01)
A61K 47/14(2017.01)
(52) Cooperative Patent Classification (CPC):
A23L 33/105; A61K 47/14; A23L 27/36; A23L 29/10; A61K 31/658; A61K 31/704; A61K 31/575; A61K 45/06; A23L 2/52; A23F 3/30; A23F 5/40; C12C 5/02; A61K 36/3482; A61K 36/742; A61K 36/82; A61K 36/3486; A61K 9/08; A61K 9/10; A61K 9/107
(86) International application number:
PCT/US2024/053080
(87) International publication number:
WO 2025/090945 (01.05.2025 Gazette 2025/18)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 27.10.2023 US 202363593947 P
24.01.2024 US 202463624664 P

(71) Applicant: Spoke Ingredient Sciences, Inc.
Bainbridge Island, Washington 98110 (US)

(72) Inventors:
  • DOUGLASS, Brad
    Bainbridge Island, Washington 98110 (US)
  • ZUBRIS, Kimberly Ann
    Bainbridge Island, Washington 98110 (US)

(74) Representative: Mathys & Squire 
32 London Bridge Street The Shard
London SE1 9SG
London SE1 9SG (GB)

   


(54) FORMULATIONS HAVING A GLYCOSIDE AND A LIPOPHILIC COMPONENT